<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Dasatinib</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Dasatinib">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Dasatinib</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Dasatinib</b>, sold under the brand name <b>Sprycel</b> among others, is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).<span class="mw-ref" id="cite_ref-AHFS2017_2-0"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+).<span class="mw-ref" id="cite_ref-AHFS2017_2-1"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is taken by mouth.<span class="mw-ref" id="cite_ref-AHFS2017_2-2"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Dasatinib</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Dasatinib.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Dasatinib.svg.png" data-file-width="512" data-file-height="170" data-file-type="drawing" height="108" width="325"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Dasatinib-2GQG-ball-and-stick.png" tppabs="https://ptable.com/wiki/compounds/I/m/Dasatinib-2GQG-ball-and-stick.png" data-file-width="5844" data-file-height="2306" data-file-type="bitmap" height="138" width="350"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Sprycel, Dasanix</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/dasatinib.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/dasatinib.html'" tppabs="https://www.drugs.com/monograph/dasatinib.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a607063.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a607063.html'" tppabs="https://medlineplus.gov/druginfo/meds/a607063.html" class="external text external">a607063</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Dasatinib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Dasatinib'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Dasatinib" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Dasatinib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Dasatinib'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Dasatinib" class="external text external">Dasatinib</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Dasatinib&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Dasatinib&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Dasatinib&SearchType=BasicSearch" class="external text external">Dasatinib</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>D<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>D (Evidence of risk)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth (tablets)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L01XE06<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L01XE06  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L01XE06'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L01XE06" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span><span class="mw-ref" id="cite_ref-1"><a href="#cite_note-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li>
<li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>96%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Liver</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>1.3 to 5 hours</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Fecal (85%), kidney (4%)</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;"><i>N</i>-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-<br>1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole<br>carboxamide monohydrate</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=302962-49-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=302962-49-8'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=302962-49-8" class="external text external">302962-49-8</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/3062316  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/3062316'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/3062316" class="external text external">3062316</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5678  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5678'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5678" class="external text external">5678</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB01254  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB01254'" tppabs="https://www.drugbank.ca/drugs/DB01254" class="external text external">DB01254</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.2323020.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.2323020.html'" tppabs="http://www.chemspider.com/Chemical-Structure.2323020.html" class="external text external">2323020</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=X78UG0A0RN  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=X78UG0A0RN'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=X78UG0A0RN" class="external text external">X78UG0A0RN</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D03658  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D03658'" tppabs="https://www.kegg.jp/entry/D03658" class="external text external">D03658</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:49375  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:49375'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:49375" class="external text external">CHEBI:49375</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1421  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1421'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1421" class="external text external">ChEMBL1421</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID4040979  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID4040979'" tppabs="https://comptox.epa.gov/dashboard/DTXSID4040979" class="external text external">DTXSID4040979</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.228.321  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.228.321'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.228.321" class="external text external">100.228.321</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>22</sub><span>H</span><sub>26</sub><span>Cl</span><span>N</span><sub>7</sub><span>O</span><sub>2</sub><span>S</span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">488.01</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=Cc1cccc%28c1NC%28%3DO%29c2cnc%28s2%29Nc3cc%28nc%28n3%29C%29N4CCN%28CC4%29CCO%29Cl  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=Cc1cccc%28c1NC%28%3DO%29c2cnc%28s2%29Nc3cc%28nc%28n3%29C%29N4CCN%28CC4%29CCO%29Cl'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=Cc1cccc%28c1NC%28%3DO%29c2cnc%28s2%29Nc3cc%28nc%28n3%29C%29N4CCN%28CC4%29CCO%29Cl" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:ZBNZXTGUTAYRHI-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458266659&page2=Dasatinib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458266659&page2=Dasatinib'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458266659&page2=Dasatinib" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Common adverse effects include low white blood cells, low blood platelets, anemia, swelling, rash, and diarrhea.<span class="mw-ref" id="cite_ref-AHFS2017_2-3"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Severe adverse effects may include bleeding, pulmonary edema, heart failure, and prolonged QT syndrome.<span class="mw-ref" id="cite_ref-AHFS2017_2-4"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Use during pregnancy may result in harm to the baby.<span class="mw-ref" id="cite_ref-AHFS2017_2-5"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is a tyrosine-kinase inhibitor and works by blocking a number of tyrosine kinases such as Bcr-Abl and the Src kinase family.<span class="mw-ref" id="cite_ref-AHFS2017_2-6"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p>Dasatinib was approved for medical use in the United States and in the European Union in 2006.<span class="mw-ref" id="cite_ref-AHFS2017_2-7"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Sprycel_EPAR_3-0"><a href="#cite_note-Sprycel_EPAR-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It is on the World Health Organization's List of Essential Medicines.<span class="mw-ref" id="cite_ref-WHO21st_4-0"><a href="#cite_note-WHO21st-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>Dasatinib is used to treat people with chronic myeloid leukemia and people with acute lymphoblastic leukemia who are positive for the Philadelphia chromosome.<span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>

<p>In the EU dasatinib is indicated for children with</p>
<ul><li>newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.<span class="mw-ref" id="cite_ref-Sprycel_EPAR_3-1"><a href="#cite_note-Sprycel_EPAR-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></li>
<li>newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.<span class="mw-ref" id="cite_ref-Sprycel_EPAR_3-2"><a href="#cite_note-Sprycel_EPAR-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></li>
<li>newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.<span class="mw-ref" id="cite_ref-Sprycel_EPAR_3-3"><a href="#cite_note-Sprycel_EPAR-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></li></ul>

<p>and adults with</p>
<ul><li>newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;<span class="mw-ref" id="cite_ref-Sprycel_EPAR_3-4"><a href="#cite_note-Sprycel_EPAR-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></li>
<li>chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;<span class="mw-ref" id="cite_ref-Sprycel_EPAR_3-5"><a href="#cite_note-Sprycel_EPAR-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></li>
<li>Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.<span class="mw-ref" id="cite_ref-Sprycel_EPAR_3-6"><a href="#cite_note-Sprycel_EPAR-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    
<p>The most common side effects are infection, suppression of the bone marrow (decreasing numbers of leukocytes, erythrocytes, and thrombocytes),<span class="mw-ref" id="cite_ref-pmid17591830_6-0"><a href="#cite_note-pmid17591830-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> headache, hemorrhage (bleeding), pleural effusion (fluid around the lungs), dyspnea (difficulty breathing), diarrhea, vomiting, nausea (feeling sick), abdominal pain (belly ache), skin rash, musculoskeletal pain, tiredness, swelling in the legs and arms and in the face, fever.<span class="mw-ref" id="cite_ref-Sprycel_EPAR_3-7"><a href="#cite_note-Sprycel_EPAR-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Neutropenia and myelosuppression were common toxic effects. Fifteen people (of 84, i.e. 18%) in the above-mentioned study developed pleural effusions, which was a suspected side effect of dasatinib. Some of these people required thoracentesis or pleurodesis to treat the effusions. Other adverse events included mild to moderate diarrhea, peripheral edema, and headache. A small number of people developed abnormal liver function tests which returned to normal without dose adjustments. Mild hypocalcemia was also noted, but did not appear to cause any significant problems. Several cases of pulmonary arterial hypertension (PAH) were found in people treated with dasatinib,<span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> possibly due to pulmonary endothelial cell damage.<span class="mw-ref" id="cite_ref-pmid29334406_8-0"><a href="#cite_note-pmid29334406-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>

<p>On October 11, 2011, the U.S. Food and Drug Administration (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (pulmonary hypertension, PAH).<span class="mw-ref" id="cite_ref-FDA_20111011_9-0"><a href="#cite_note-FDA_20111011-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs).<span class="mw-ref" id="cite_ref-FDA_20111011_9-1"><a href="#cite_note-FDA_20111011-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> In reported cases, people developed PAH after starting dasatinib, including after more than one year of treatment.<span class="mw-ref" id="cite_ref-FDA_20111011_9-2"><a href="#cite_note-FDA_20111011-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Information about the risk was added to the Warnings and Precautions section of the Sprycel drug label.<span class="mw-ref" id="cite_ref-FDA_20111011_9-3"><a href="#cite_note-FDA_20111011-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    
<div class="thumb tleft"><div class="thumbinner" style="width:252px"><img src="../I/m/2GQG_Abl1Kinase_Dasatinib.png" tppabs="https://ptable.com/wiki/compounds/I/m/2GQG_Abl1Kinase_Dasatinib.png" data-file-width="1102" data-file-height="847" data-file-type="bitmap" height="192" width="250"><div class="thumbcaption" style="text-align: left">Crystal structure<span class="mw-ref" id="cite_ref-pmid16740718_10-0"><a href="#cite_note-pmid16740718-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> (<a href="javascript:if(confirm('http://www.pdb.org/pdb/explore.do?structureId=2GQG  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pdb.org/pdb/explore.do?structureId=2GQG'" tppabs="http://www.pdb.org/pdb/explore.do?structureId=2GQG" class="external text external">PDB 2GQG</a>) of Abl kinase domain (blue) in complex with dasatinib (red).</div></div></div>
<p>Dasatinib is an ATP-competitive protein tyrosine kinase inhibitor. The main targets of dasatinib are BCR/Abl (the "Philadelphia chromosome"), Src, c-Kit, ephrin receptors, and several other tyrosine kinases.<span class="mw-ref" id="cite_ref-pmid32664269_11-0"><a href="#cite_note-pmid32664269-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> Strong inhibition of the activated BCR-ABL kinase distinguishes dasatinib from other CML treatments, such as <a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">imatinib</a> and nilotinib.<span class="mw-ref" id="cite_ref-pmid32664269_11-1"><a href="#cite_note-pmid32664269-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-pmid32289275_12-0"><a href="#cite_note-pmid32289275-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> Although dasatinib only has a plasma half-life of three to five hours, the strong binding to BCR-ABL1 results in a longer duration of action.<span class="mw-ref" id="cite_ref-pmid32289275_12-1"><a href="#cite_note-pmid32289275-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    

<p>Dasatinib was developed by collaboration of Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd,<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> and named for Bristol-Myers Squibb research fellow Jagabandhu Das, whose program leader says that the drug would not have come into existence had he not challenged some of the medicinal chemists' underlying assumptions at a time when progress in the development of the molecule had stalled.<span class="mw-ref" id="cite_ref-Drahl2012_16-0"><a href="#cite_note-Drahl2012-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Legal_status">Legal status</h3></summary>
    
<p>Dasatinib was approved for used in the United States in June 2006 and in the European Union in November 2006<span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span><span class="mw-ref" id="cite_ref-Sprycel_EPAR_3-8"><a href="#cite_note-Sprycel_EPAR-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>

<p>In October 2010, dasatinib was approved in the United States for the treatment of newly diagnosed adults with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (CP-CML).<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>

<p>In November 2017, dasatinib was approved in the United States for the treatment of children with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.<span class="mw-ref" id="cite_ref-FDA_PR_20171109_19-0"><a href="#cite_note-FDA_PR_20171109-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>

<p>Approval was based on data from 97 pediatric participants with chronic phase CML evaluated in two trials—a Phase I, open-label, non-randomized, dose-ranging trial and a Phase II, open-label, non-randomized trial.<span class="mw-ref" id="cite_ref-FDA_PR_20171109_19-1"><a href="#cite_note-FDA_PR_20171109-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> Fifty-one participants exclusively from the Phase II trial were newly diagnosed with chronic phase CML and 46 participants (17 from the Phase I trial and 29 from the Phase II trial) were resistant or intolerant to previous treatment with imatinib.<span class="mw-ref" id="cite_ref-FDA_PR_20171109_19-2"><a href="#cite_note-FDA_PR_20171109-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> The majority of participants were treated with dasatinib tablets 60<span>&nbsp;</span>mg/m<sup>2</sup> body surface area once daily.<span class="mw-ref" id="cite_ref-FDA_PR_20171109_19-3"><a href="#cite_note-FDA_PR_20171109-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> Participants were treated until disease progression or unacceptable toxicity.<span class="mw-ref" id="cite_ref-FDA_PR_20171109_19-4"><a href="#cite_note-FDA_PR_20171109-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Economics">Economics</h3></summary>
    
<p>The Union for Affordable Cancer Treatment objected to the price of dasatinib, in a letter to the U.S. trade representative. The average wholesale price in the U.S. is $367 per day, twice the price in other high income countries. The price in India, where the average annual per capita income is $1,570, and where most people pay out of pocket, is Rs6627 ($108) a day. Indian manufacturers offered to supply generic versions for $4 a day, but, under pressure from the U.S., the Indian Department of Industrial Policy and Promotion refused to issue a compulsory license.<span class="mw-ref" id="cite_ref-Cost2014_20-0"><a href="#cite_note-Cost2014-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>

<p>Bristol-Myers Squibb justified the high prices of cancer drugs with the high R&amp;D costs, but the Union of Affordable Cancer Treatment said that most of the R&amp;D costs came from the U.S. government, including National Institutes of Health funded research and clinical trials, and a 50% tax credit. In England and Wales, the National Institute for Health and Care Excellence recommended against dasatinib because of the high cost-benefit ratio.<span class="mw-ref" id="cite_ref-Cost2014_20-1"><a href="#cite_note-Cost2014-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>

<p>The Union for Affordable Cancer Treatment said that "the dasatinib dispute illustrates the shortcomings of US trade policy and its impact on cancer patients"<span class="mw-ref" id="cite_ref-Cost2014_20-2"><a href="#cite_note-Cost2014-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Brand_names">Brand names</h3></summary>
    
<p>In Bangladesh dasatinib is available under the trade name Dasanix by Beacon Pharmaceuticals.In India, It is marketed by brand name NEXTKI by EMCURE PHARMACEUTICALS</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    
<p>Dasatinib has been shown to eliminate senescent cells in cultured adipocyte progenitor cells.<span class="mw-ref" id="cite_ref-pmid32686219_21-0"><a href="#cite_note-pmid32686219-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> Dasatinib has been shown to induce apoptosis in senescent cells by inhibiting Src kinase, whereas <a href="Quercetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Quercetin" title="Quercetin">quercetin</a> inhibits the anti-apoptotic protein Bcl-xL.<span class="mw-ref" id="cite_ref-pmid32686219_21-1"><a href="#cite_note-pmid32686219-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> Administration of dasatinib along with quercetin to mice improved cardiovascular function and eliminated senescent cells.<span class="mw-ref" id="cite_ref-pmid31746100_22-0"><a href="#cite_note-pmid31746100-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> Aged mice given dasatinib with querceting showed improved health and survival.<span class="mw-ref" id="cite_ref-pmid31746100_22-1"><a href="#cite_note-pmid31746100-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>

<p>Giving dasatinib and quercetin to mice eliminated senescent cells and caused a long-term resolution of frailty.<span class="mw-ref" id="cite_ref-pmid32752135_23-0"><a href="#cite_note-pmid32752135-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> A study of fourteen human patients suffering from idiopathic pulmonary fibrosis (a disease characterized by increased numbers of senescent cells) given dasatinib and quercetin showed improved physical function and evidence of reduced senescent cells.<span class="mw-ref" id="cite_ref-pmid32686219_21-2"><a href="#cite_note-pmid32686219-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-1"> <span id="mw-reference-text-cite_note-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02657-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02657-3'" tppabs="https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02657-3" class="external text external">"Sprycel (Dasatinib)"</a>. <i>TGA</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 July</span> 2020</span>.</cite></span></li><li id="cite_note-AHFS2017-2"> <span id="mw-reference-text-cite_note-AHFS2017-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/dasatinib.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/dasatinib.html'" tppabs="https://www.drugs.com/monograph/dasatinib.html" class="external text external">"Dasatinib"</a>. The American Society of Health-System Pharmacists<span class="reference-accessdate">. Retrieved <span class="nowrap">8 December</span> 2017</span>.</cite></span></li><li id="cite_note-Sprycel_EPAR-3"> <span id="mw-reference-text-cite_note-Sprycel_EPAR-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel" class="external text external">"Sprycel EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">28 April</span> 2020</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-WHO21st-4"> <span id="mw-reference-text-cite_note-WHO21st-4" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a></span>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite id="CITEREFKeating2017" class="citation journal cs1">Keating GM (January 2017). "Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia". <i>Drugs</i>. <b>77</b> (1): 85–96. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs40265-016-0677-x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs40265-016-0677-x'" tppabs="https://doi.org/10.1007%2Fs40265-016-0677-x" class="external text external">10.1007/s40265-016-0677-x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28032244  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28032244'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28032244" class="external text external">28032244</a>.</cite></span></li><li id="cite_note-pmid17591830-6"> <span id="mw-reference-text-cite_note-pmid17591830-6" class="mw-reference-text"><cite id="CITEREFOlivieriManzione2007" class="citation journal cs1">Olivieri, A.; Manzione, L. (2007). "Dasatinib: a new step in molecular target therapy". <i>Annals of Oncology</i>. 18 Suppl 6: vi42–vi46. doi:<a href="javascript:if(confirm('https://doi.org/10.1093%2Fannonc%2Fmdm223  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Fannonc%2Fmdm223'" tppabs="https://doi.org/10.1093%2Fannonc%2Fmdm223" class="external text external">10.1093/annonc/mdm223</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17591830  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17591830'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17591830" class="external text external">17591830</a>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://archive.is/20130505141147/http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---August/16/Healthcare-professional-communication-regarding-association-of-dasatinib-Sprycel-with-pulmonary-arterial-hypertension/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.is/20130505141147/http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---August/16/Healthcare-professional-communication-regarding-association-of-dasatinib-Sprycel-with-pulmonary-arterial-hypertension/'" tppabs="https://archive.is/20130505141147/http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---August/16/Healthcare-professional-communication-regarding-association-of-dasatinib-Sprycel-with-pulmonary-arterial-hypertension/" class="external text external">"NHS - Healthcare News"</a>. <i>nelm.nhs.uk</i>. Archived from <a href="javascript:if(confirm('http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---August/16/Healthcare-professional-communication-regarding-association-of-dasatinib-Sprycel-with-pulmonary-arterial-hypertension/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---August/16/Healthcare-professional-communication-regarding-association-of-dasatinib-Sprycel-with-pulmonary-arterial-hypertension/'" tppabs="http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---August/16/Healthcare-professional-communication-regarding-association-of-dasatinib-Sprycel-with-pulmonary-arterial-hypertension/" class="external text external">the original</a> on 5 May 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">27 September</span> 2011</span>.</cite></span></li><li id="cite_note-pmid29334406-8"> <span id="mw-reference-text-cite_note-pmid29334406-8" class="mw-reference-text"><cite id="CITEREFYurttaşEşkazan2018" class="citation journal cs1">Yurttaş NO, Eşkazan AE (2018). <a href="javascript:if(confirm('https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13508  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13508'" tppabs="https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13508" class="external text external">"Dasatinib-induced pulmonary arterial hypertension"</a>. <i>British Journal of Clinical Pharmacology</i>. <b>84</b> (5): 835–845. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fbcp.13508  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fbcp.13508'" tppabs="https://doi.org/10.1111%2Fbcp.13508" class="external text external">10.1111/bcp.13508</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903230  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903230'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903230" class="external text external">5903230</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29334406  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29334406'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29334406" class="external text external">29334406</a>.</cite></span></li><li id="cite_note-FDA_20111011-9"> <span id="mw-reference-text-cite_note-FDA_20111011-9" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-sprycel-dasatinib-and-risk-pulmonary-arterial-hypertension  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-sprycel-dasatinib-and-risk-pulmonary-arterial-hypertension'" tppabs="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-sprycel-dasatinib-and-risk-pulmonary-arterial-hypertension" class="external text external">"Sprycel (dasatinib) and risk of pulmonary arterial hypertension"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 23 September 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">28 April</span> 2020</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-pmid16740718-10"> <span id="mw-reference-text-cite_note-pmid16740718-10" class="mw-reference-text"><cite id="CITEREFTokarskiNewittChangCheng2006" class="citation journal cs1">Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE,  et al. (June 2006). <a href="javascript:if(confirm('https://doi.org/10.1158/0008-5472.CAN-05-4187  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1158/0008-5472.CAN-05-4187'" tppabs="https://doi.org/10.1158/0008-5472.CAN-05-4187" class="external text external">"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants"</a>. <i>Cancer Research</i>. <b>66</b> (11): 5790–7. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1158%2F0008-5472.CAN-05-4187  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1158%2F0008-5472.CAN-05-4187'" tppabs="https://doi.org/10.1158%2F0008-5472.CAN-05-4187" class="external text external">10.1158/0008-5472.CAN-05-4187</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16740718  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16740718'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16740718" class="external text external">16740718</a>.</cite></span></li><li id="cite_note-pmid32664269-11"> <span id="mw-reference-text-cite_note-pmid32664269-11" class="mw-reference-text"><cite id="CITEREFPiscitaniSirolliMorroniBonomini2020" class="citation journal cs1">Piscitani L, Sirolli V, Morroni M, Bonomini M (2020). <a href="javascript:if(confirm('https://www.mdpi.com/1422-0067/21/14/4878  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.mdpi.com/1422-0067/21/14/4878'" tppabs="https://www.mdpi.com/1422-0067/21/14/4878" class="external text external">"Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations"</a>. <i>International Journal of Molecular Sciences</i>. <b>21</b> (14): e4878. doi:<a href="javascript:if(confirm('https://doi.org/10.3390%2Fijms21144878  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3390%2Fijms21144878'" tppabs="https://doi.org/10.3390%2Fijms21144878" class="external text external">10.3390/ijms21144878</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/32664269  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/32664269'" tppabs="https://pubmed.ncbi.nlm.nih.gov/32664269" class="external text external">32664269</a>.</cite></span></li><li id="cite_note-pmid32289275-12"> <span id="mw-reference-text-cite_note-pmid32289275-12" class="mw-reference-text"><cite id="CITEREFBraunEideDruker2020" class="citation journal cs1">Braun TP, Eide CA, Druker BJ (2020). "Response and Resistance to BCR-ABL1-Targeted Therapies". <i>Cancer Cell (journal)</i>. <b>37</b> (4): 530–542. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ccell.2020.03.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ccell.2020.03.006'" tppabs="https://doi.org/10.1016%2Fj.ccell.2020.03.006" class="external text external">10.1016/j.ccell.2020.03.006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/32289275  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/32289275'" tppabs="https://pubmed.ncbi.nlm.nih.gov/32289275" class="external text external">32289275</a>.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.otsuka.co.jp/en/company/release/2015/0302_01.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.otsuka.co.jp/en/company/release/2015/0302_01.html'" tppabs="https://www.otsuka.co.jp/en/company/release/2015/0302_01.html" class="external text external">"Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area"</a>.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('http://news.bms.com/press-release/rd-news/fda-approves-us-product-labeling-update-sprycel-dasatinib-include-three-year-f  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://news.bms.com/press-release/rd-news/fda-approves-us-product-labeling-update-sprycel-dasatinib-include-three-year-f'" tppabs="http://news.bms.com/press-release/rd-news/fda-approves-us-product-labeling-update-sprycel-dasatinib-include-three-year-f" class="external text external">"FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Three-Year First-Line and Five-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase"</a>. <i>Bristol-Myers Squibb</i> (Press release).</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('http://news.bms.com/press-release/financial-news/bristol-myers-squibb-announces-extension-us-agreement-abilify-and-estab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://news.bms.com/press-release/financial-news/bristol-myers-squibb-announces-extension-us-agreement-abilify-and-estab'" tppabs="http://news.bms.com/press-release/financial-news/bristol-myers-squibb-announces-extension-us-agreement-abilify-and-estab" class="external text external">"Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY and Establishment of an Oncology Collaboration with Otsuka"</a>. <i>Bristol-Myers Squibb</i> (Press release).</cite></span></li><li id="cite_note-Drahl2012-16"> <span id="mw-reference-text-cite_note-Drahl2012-16" class="mw-reference-text"><cite id="CITEREFDrahl2012" class="citation web cs1">Drahl C (16 January 2012). <a href="javascript:if(confirm('http://cenblog.org/the-haystack/2012/01/jagabandhu-das-dasatinib/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://cenblog.org/the-haystack/2012/01/jagabandhu-das-dasatinib/'" tppabs="http://cenblog.org/the-haystack/2012/01/jagabandhu-das-dasatinib/" class="external text external">"How Jagabandhu Das made dasatinib possible"</a>. <i>The Safety Zone blog</i>. Chemical &amp; Engineering News<span class="reference-accessdate">. Retrieved <span class="nowrap">29 August</span> 2016</span>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021986_022072_SprycelTOC.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021986_022072_SprycelTOC.cfm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021986_022072_SprycelTOC.cfm" class="external text external">"Drug Approval Package: Sprycel (Dasatinib) NDA #021986 &amp; 022072"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 6 September 2006<span class="reference-accessdate">. Retrieved <span class="nowrap">28 April</span> 2020</span>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/resources-information-approved-drugs/2010-notifications  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/resources-information-approved-drugs/2010-notifications'" tppabs="https://www.fda.gov/drugs/resources-information-approved-drugs/2010-notifications" class="external text external">"2010 Notifications"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 18 November 2010<span class="reference-accessdate">. Retrieved <span class="nowrap">28 April</span> 2020</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-FDA_PR_20171109-19"> <span id="mw-reference-text-cite_note-FDA_PR_20171109-19" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dasatinib-pediatric-patients-cml  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dasatinib-pediatric-patients-cml'" tppabs="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dasatinib-pediatric-patients-cml" class="external text external">"FDA approves dasatinib for pediatric patients with CML"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 9 November 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">28 April</span> 2020</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-Cost2014-20"> <span id="mw-reference-text-cite_note-Cost2014-20" class="mw-reference-text"><cite id="CITEREFCohen2014" class="citation journal cs1">Cohen D (November 2014). "US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says". <i>BMJ</i>. <b>349</b>: g6593. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.g6593  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.g6593'" tppabs="https://doi.org/10.1136%2Fbmj.g6593" class="external text external">10.1136/bmj.g6593</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25370846  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25370846'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25370846" class="external text external">25370846</a>.</cite></span></li><li id="cite_note-pmid32686219-21"> <span id="mw-reference-text-cite_note-pmid32686219-21" class="mw-reference-text"><cite id="CITEREFKirklandTchkonia2020" class="citation journal cs1">Kirkland JL, Tchkonia T (2020). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405395  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405395'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405395" class="external text external">"Senolytic drugs: from discovery to translation"</a>. <i>Journal of Internal Medicine</i>. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fjoim.13141  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fjoim.13141'" tppabs="https://doi.org/10.1111%2Fjoim.13141" class="external text external">10.1111/joim.13141</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405395  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405395'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405395" class="external text external">7405395</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/32686219  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/32686219'" tppabs="https://pubmed.ncbi.nlm.nih.gov/32686219" class="external text external">32686219</a>.</cite></span></li><li id="cite_note-pmid31746100-22"> <span id="mw-reference-text-cite_note-pmid31746100-22" class="mw-reference-text"><cite id="CITEREFPaez-RibesGonzález-GualdaDohertyMuñoz-Espín2019" class="citation journal cs1">Paez-Ribes M, González-Gualda E, Doherty GJ, Muñoz-Espín D (2019). <a href="javascript:if(confirm('https://www.embopress.org/doi/full/10.15252/emmm.201810234  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.embopress.org/doi/full/10.15252/emmm.201810234'" tppabs="https://www.embopress.org/doi/full/10.15252/emmm.201810234" class="external text external">"Targeting senescent cells in translational medicine"</a>. <i>EMBO Molecular Medicine</i>. <b>11</b> (12): e10234. doi:<a href="javascript:if(confirm('https://doi.org/10.15252%2Femmm.201810234  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.15252%2Femmm.201810234'" tppabs="https://doi.org/10.15252%2Femmm.201810234" class="external text external">10.15252/emmm.201810234</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895604  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895604'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895604" class="external text external">6895604</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31746100  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31746100'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31746100" class="external text external">31746100</a>.</cite></span></li><li id="cite_note-pmid32752135-23"> <span id="mw-reference-text-cite_note-pmid32752135-23" class="mw-reference-text"><cite id="CITEREFWyldBellantuonoTchkoniaDanson2020" class="citation journal cs1">Wyld L, Bellantuono I, Tchkonia T, Danson S, Kirkland JL (2020). <a href="javascript:if(confirm('https://www.mdpi.com/2072-6694/12/8/2134  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.mdpi.com/2072-6694/12/8/2134'" tppabs="https://www.mdpi.com/2072-6694/12/8/2134" class="external text external">"Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies"</a>. <i>CANCERS</i>. <b>12</b> (8): e2134. doi:<a href="javascript:if(confirm('https://doi.org/10.3390%2Fcancers12082134  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3390%2Fcancers12082134'" tppabs="https://doi.org/10.3390%2Fcancers12082134" class="external text external">10.3390/cancers12082134</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/32752135  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/32752135'" tppabs="https://pubmed.ncbi.nlm.nih.gov/32752135" class="external text external">32752135</a>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Further_reading">Further reading</h2></summary>
    
<style data-mw-deduplicate="TemplateStyles:r886047268">.mw-parser-output .refbegin{font-size:90%;margin-bottom:0.5em}.mw-parser-output .refbegin-hanging-indents>ul{list-style-type:none;margin-left:0}.mw-parser-output .refbegin-hanging-indents>ul>li,.mw-parser-output .refbegin-hanging-indents>dl>dd{margin-left:0;padding-left:3.2em;text-indent:-3.2em;list-style:none}.mw-parser-output .refbegin-100{font-size:100%}</style><div class="refbegin reflist   " style="">
<ul><li><cite id="CITEREFLombardoLeeChenNorris2004" class="citation journal cs1">Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K,  et al. (December 2004). "Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays". <i>Journal of Medicinal Chemistry</i>. <b>47</b> (27): 6658–61. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Fjm049486a  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Fjm049486a'" tppabs="https://doi.org/10.1021%2Fjm049486a" class="external text external">10.1021/jm049486a</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15615512  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15615512'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15615512" class="external text external">15615512</a>.</cite></li></ul>
</div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/rn/302962-49-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/rn/302962-49-8'" tppabs="https://druginfo.nlm.nih.gov/drugportal/rn/302962-49-8" class="external text external">"Dasatinib"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em">Targeted cancer therapy / antineoplastic agents (L01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">CI monoclonal antibodies ("-mab")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (<a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Panitumumab)</li>
<li><i>HER2/neu</i> (Pertuzumab, <a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a> (+hyaluronidase)</li>
<li>Trastuzumab emtansine)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others for solid tumors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>EpCAM</i> (Catumaxomab</li>
<li>Edrecolomab)</li>
<li><i>VEGF-A</i> (Bevacizumab)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Leukemia/lymphoma</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>lymphoid: <i>CD20</i> (<a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab</a></li>
<li>Obinutuzumab</li>
<li>Ofatumumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a>), <i>CD30</i> (Brentuximab), <i>CD52</i> (<a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>)</li></ul>

<ul><li>myeloid: <i>CD33</i> (Gemtuzumab)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Tyrosine kinase inhibitors ("-nib")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (Brigatinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Olmutinib</li>
<li>Osimertinib</li>
<li>Rociletinib</li>
<li>Vandetanib)</li>
<li><i>HER1/EGFR and HER2/neu</i>
<ul><li>Afatinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li></ul></li></ul>

<ul><li>RTK class III: <i>C-kit and PDGFR</i> (Axitinib</li>
<li>Masitinib</li>
<li>Pazopanib</li>
<li>Ripretinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib)</li>
<li><i>FLT3</i> (Lestaurtinib)</li></ul>

<ul><li><i>VEGFR</i>
<ul><li>Axitinib</li>
<li>Cediranib</li>
<li>Lenvatinib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Tivozanib</li>
<li>Toceranib</li>
<li>Vandetanib</li></ul></li></ul>

<ul><li><i>ALK</i> 
<ul><li>Alectinib</li>
<li>Brigatinib</li>
<li>Ceritinib</li></ul></li></ul>

<p><i>RET inhibitors:</i> Entrectinib (ALK, ROS1, NTRK), Pemigatinib (FGFR), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).
<i>c-MET inhibitors:</i> Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK)</p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-receptor</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>bcr-abl</i>
<ul><li>Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Nilotinib</li>
<li>Ponatinib</li>
<li>Radotinib</li></ul></li></ul>

<ul><li><i>Src</i> (Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a>)</li></ul>

<ul><li><i>Janus kinase</i>
<ul><li>Lestaurtinib</li>
<li>Momelotinib</li>
<li>Pacritinib</li>
<li>Ruxolitinib</li></ul></li></ul>

<ul><li><i>MAP2K</i>
<ul><li>Binimetinib</li>
<li>Cobimetinib</li>
<li>Selumetinib</li>
<li>Trametinib</li></ul></li></ul>

<ul><li><i>EML4-ALK</i>
<ul><li>Crizotinib</li>
<li>Entrectinib</li>
<li>Lorlatinib</li></ul></li></ul>

<ul><li><i>Bruton's</i>
<ul><li>Acalabrutinib</li>
<li>Ibrutinib</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>fusion protein against VEGF</i> (Aflibercept)</li>
<li><i>proapoptotic peptide against ANXA2 and prohibitin</i> (Adipotide)</li>
<li><i>exotoxin against <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a></i> (<a href="Denileukin_diftitox.htm" tppabs="https://ptable.com/wiki/compounds/A/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a>)</li>
<li><i>mTOR inhibitors</i>
<ul><li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li></ul></li>
<li><i>hedgehog inhibitors</i>
<ul><li>Sonidegib</li>
<li>Vismodegib</li></ul></li>
<li><i>CDK inhibitor</i> (Palbociclib</li>
<li>Ribociclib)</li>
<li>Venetoclax</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Growth_factor_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Growth_factor_receptor_modulators" style="font-size:114%;margin:0 4em">Growth factor receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Angiopoietin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Angiopoietin 1</li>
<li>Angiopoietin 4</li></ul>

<ul><li><i>Antagonists:</i> Angiopoietin 2</li>
<li><span class="new">Angiopoietin 3</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">CE-245677</span></li>
<li>Rebastinib</li></ul>

<ul><li><i>Antibodies:</i> Evinacumab (against angiopoietin 3)</li>
<li>Nesvacumab (against angiopoietin 2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CNTF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Axokine</li>
<li>CNTF</li>
<li><span class="new">Dapiclermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF (ErbB)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF<br><small>(ErbB1/HER1)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Amphiregulin</li>
<li>Betacellulin</li>
<li>EGF (urogastrone)</li>
<li>Epigen</li>
<li>Epiregulin</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Murodermin</li>
<li>Nepidermin</li>
<li>Transforming growth factor alpha (TGFα)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><span class="new">Agerafenib</span></li>
<li>Brigatinib</li>
<li>Canertinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Grandinin</li>
<li>Icotinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li>
<li>Osimertinib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> <a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li><span class="new">Depatuxizumab</span></li>
<li>Depatuxizumab mafodotin</li>
<li>Futuximab</li>
<li>Imgatuzumab</li>
<li>Matuzumab</li>
<li>Necitumumab</li>
<li>Nimotuzumab</li>
<li>Panitumumab</li>
<li>Zalutumumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB2/HER2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: <i>Unknown/none</i></li></ul>

<ul><li><i>Antibodies:</i> Ertumaxomab</li>
<li>Pertuzumab</li>
<li><a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a></li>
<li><span class="new">Trastuzumab duocarmazine</span></li>
<li>Trastuzumab emtansine</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Mubritinib</li>
<li>Neratinib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB3/HER3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))</li></ul>

<ul><li><i>Antibodies:</i> Duligotumab</li>
<li>Patritumab</li>
<li>Seribantumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB4/HER4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Betacellulin</li>
<li>Epigen</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Neuregulins (heregulins) (1, 2, 3, 4, <span class="new">5 (tomoregulin, TMEFF)</span>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)</li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Trafermin</li>
<li><span class="new">Velafermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22)</li>
<li><a href="Palifermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Palifermin" title="Palifermin">Palifermin</a></li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">Aprutumab</span></li>
<li><span class="new">Aprutumab ixadotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 8, 9, 18, 23)</li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> Burosumab (against FGF23)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 6, 8, 9, 19)</li>
<li>Trafermin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> FGF15/19</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">HGF (c-Met)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Hepatocyte growth factor</li></ul>

<ul><li><i>Potentiators:</i> Dihexa (PNB-0408)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AM7</span></li>
<li><span class="new">AMG-458</span></li>
<li><span class="new">Amuvatinib</span></li>
<li><span class="new">BMS-777607</span></li>
<li>Cabozantinib</li>
<li>Crizotinib</li>
<li>Foretinib</li>
<li><span class="new">Golvatinib</span></li>
<li><span class="new">INCB28060</span></li>
<li><span class="new">JNJ-38877605</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li><span class="new">MK-2461</span></li>
<li><span class="new">PF-04217903</span></li>
<li><span class="new">PF-2341066</span></li>
<li><span class="new">PHA-665752</span></li>
<li><span class="new">SU-11274</span></li>
<li>Tivantinib</li>
<li>Volitinib</li></ul>

<ul><li><i>Antibodies:</i> Emibetuzumab</li>
<li>Ficlatuzumab</li>
<li>Flanvotumab</li>
<li>Onartuzumab</li>
<li>Rilotumumab</li>
<li><span class="new">Telisotuzumab</span></li>
<li><span class="new">Telisotuzumab vedotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: des(1-3)IGF-1</li>
<li>Insulin-like growth factor-1 (somatomedin C)</li>
<li>IGF-1 LR3</li>
<li>Insulin-like growth factor-2 (somatomedin A)</li>
<li><a href="Insulin.htm" tppabs="https://ptable.com/wiki/compounds/A/Insulin" title="Insulin">Insulin</a></li>
<li><a href="Mecasermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Mecasermin" title="Mecasermin">Mecasermin</a></li>
<li>Mecasermin rinfabate</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">BMS-754807</span></li>
<li>Linsitinib</li>
<li><span class="new">NVP-ADW742</span></li>
<li><span class="new">NVP-AEW541</span></li>
<li><span class="new">OSl-906</span></li></ul>

<ul><li><i>Antibodies:</i> <span class="new">AVE-1642</span></li>
<li>Cixutumumab</li>
<li>Dalotuzumab</li>
<li>Figitumumab</li>
<li>Ganitumab</li>
<li>Robatumumab</li>
<li><span class="new">R1507</span></li>
<li>Teprotumumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Insulin-like growth factor-2 (somatomedin A)</li></ul>

<ul><li><i>Antibodies:</i> Dusigitumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Binding proteins:</i> IGFBP (1, 2, 3, 4, 5, 6, 7)</li></ul>

<ul><li><i>Cleavage products/derivatives with unknown target:</i> <span class="new">Glypromate (GPE, (1-3)IGF-1)</span></li>
<li>Trofinetide</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">LNGF (p75<sup>NTR</sup>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BDNF</li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li>NGF</li>
<li>NT-3</li>
<li>NT-4</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li><span class="new">EVT-901 (SAR-127963)</span></li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Antibodies:</i> <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">LEVI-04 (p75<sup>NTR</sup>-Fc)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">PDGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Becaplermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Becaplermin" title="Becaplermin">Becaplermin</a></li>
<li>Platelet-derived growth factor (A, B, C, D)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li>Crenolanib</li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Lenvatinib</li>
<li>Masitinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Radotinib</li>
<li>Quizartinib</li>
<li>Ripretinib</li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li>Toceranib</li></ul>

<ul><li><i>Antibodies:</i> Olaratumab</li>
<li>Ramucirumab</li>
<li>Tovetumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">RET (GFL)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Glial cell line-derived neurotrophic factor (GDNF)</li>
<li><span class="new">Liatermin</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neurturin (NRTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα3</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Artemin (ARTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα4</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Persephin (PSPN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">SCF (c-Kit)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Ancestim</li>
<li>Stem cell factor</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Masitinib</li>
<li>Nilotinib</li>
<li>Pazopanib</li>
<li>Quizartinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TGFβ</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Trk</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkA</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li><span class="new">Gambogic amide</span></li>
<li>NGF</li>
<li>Tavilermide</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li>FX007</li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Negative allosteric modulators:</i> <span class="new">VM-902A</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">Milciclib</span></li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li>
<li>Rebastinib</li>
<li><span class="new">SNA-120 (pegylated K252a)</span>)</li></ul>

<ul><li><i>Antibodies:</i> <i>Against TrkA:</i> <span class="new">GBR-900</span>; <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">ReN-1820 (TrkAd5)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkB</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">3,7-DHF</span></li>
<li><span class="new">3,7,8,2'-THF</span></li>
<li>4'-DMA-7,8-DHF</li>
<li><span class="new">7,3'-DHF</span></li>
<li>7,8-DHF</li>
<li><span class="new">7,8,2'-THF</span></li>
<li>7,8,3'-THF</li>
<li><a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BDNF</li>
<li>BNN-20</li>
<li>Deoxygedunin</li>
<li><a href="Selegiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Deprenyl" title="Deprenyl" class="mw-redirect">Deprenyl</a></li>
<li>Diosmetin</li>
<li><span class="new">DMAQ-B1</span></li>
<li>HIOC</li>
<li>LM22A-4</li>
<li><a href="N-Acetylserotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/N-Acetylserotonin" title="N-Acetylserotonin">N-Acetylserotonin</a></li>
<li>NT-3</li>
<li>NT-4</li>
<li>Norwogonin (5,7,8-THF)</li>
<li>R7</li>
<li>R13</li>
<li><span class="new">TDP6</span></li></ul>

<ul><li><i>Antagonists:</i> ANA-12</li>
<li>Cyclotraxin B</li>
<li>Gossypetin (3,5,7,8,3',4'-HHF)</li></ul>

<ul><li><i>Ligands:</i> <a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkC</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BNN-20</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li>NT-3</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">VEGF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Placental growth factor (PGF)</li>
<li>Ripretinib</li>
<li><span class="new">Telbermin</span></li>
<li>VEGF (A, B, C, D (FIGF))</li></ul>

<ul><li><i>Allosteric modulators:</i> Cyclotraxin B</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li><span class="new">Altiratinib</span></li>
<li>Axitinib</li>
<li>Cabozantinib</li>
<li>Cediranib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Lenvatinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Pegaptanib</li>
<li>Rebastinib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li>
<li>Tivozanib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> Alacizumab pegol</li>
<li>Bevacizumab</li>
<li>Icrucumab</li>
<li>Ramucirumab</li>
<li><a href="Ranibizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Ranibizumab" title="Ranibizumab">Ranibizumab</a></li></ul>

<ul><li><i>Decoy receptors:</i> Aflibercept</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Additional growth factors:</i> Adrenomedullin</li>
<li>Colony-stimulating factors (see here instead)</li>
<li>Connective tissue growth factor (CTGF)</li>
<li>Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)</li>
<li>Erythropoietin (see here instead)</li>
<li>Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)</li>
<li>Glia maturation factor (GMF)</li>
<li>Hepatoma-derived growth factor (HDGF)</li>
<li>Interleukins/T-cell growth factors (see here instead)</li>
<li>Leukemia inhibitory factor (LIF)</li>
<li>Macrophage-stimulating protein (MSP; HLP, HGFLP)</li>
<li>Midkine (NEGF2)</li>
<li>Migration-stimulating factor (MSF; PRG4)</li>
<li>Oncomodulin</li>
<li>Pituitary adenylate cyclase-activating peptide (PACAP)</li>
<li>Pleiotrophin</li>
<li>Renalase</li>
<li>Thrombopoietin (see here instead)</li>
<li>Wnt signaling proteins</li></ul>

<ul><li><i>Additional growth factor receptor modulators:</i> Cerebrolysin (neurotrophin mixture)</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Cytokine receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Piperazines" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Piperazines" style="font-size:114%;margin:0 4em"><a href="Piperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Piperazine" title="Piperazine">Piperazines</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Simple piperazines<br><small>(no additional rings)</small></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>1-Cyclohexylpiperazine</li>
<li><a href="Aminoethylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminoethylpiperazine" title="Aminoethylpiperazine">Aminoethylpiperazine</a></li>
<li><a href="Diethylcarbamazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Diethylcarbamazine" title="Diethylcarbamazine">Diethylcarbamazine</a></li>
<li>HEPPS</li>
<li>Midafotel</li>
<li><a href="Piperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Piperazine" title="Piperazine">Piperazine</a></li>
<li>PIPES</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Phenylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylpiperazine" title="Phenylpiperazine">Phenylpiperazines</a></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>2C-B-PP</li>
<li>3,4-CFP</li>
<li>Acaprazine</li>
<li><a href="Antrafenine.htm" tppabs="https://ptable.com/wiki/compounds/A/Antrafenine" title="Antrafenine">Antrafenine</a></li>
<li><a href="Aripiprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Aripiprazole" title="Aripiprazole">Aripiprazole</a></li>
<li>Batoprazine</li>
<li>Bifeprunox</li>
<li>BRL-15,572</li>
<li>Ciprofloxacin</li>
<li>CSP-2503</li>
<li><a href="Dapiprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Dapiprazole" title="Dapiprazole">Dapiprazole</a></li>
<li>DCPP</li>
<li>DMPP</li>
<li>Diphenylpiperazine</li>
<li><a href="Dropropizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dropropizine" title="Dropropizine">Dropropizine</a></li>
<li>EGIS-12,233</li>
<li>Elopiprazole</li>
<li>Eltoprazine</li>
<li>Enpiprazole</li>
<li>Ensaculin</li>
<li>Etoperidone</li>
<li>Flesinoxan</li>
<li>Fluanisone</li>
<li>Flibanserin</li>
<li>Fluprazine</li>
<li><a href="Itraconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Itraconazole" title="Itraconazole">Itraconazole</a></li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li>Levodropropizine</li>
<li>Lorpiprazole</li>
<li><a href="Meta-Chlorophenylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Meta-Chlorophenylpiperazine" title="Meta-Chlorophenylpiperazine">mCPP</a></li>
<li>Mefway</li>
<li>MeOPP</li>
<li>Mepiprazole</li>
<li><a href="Naftopidil.htm" tppabs="https://ptable.com/wiki/compounds/A/Naftopidil" title="Naftopidil">Naftopidil</a></li>
<li>Naluzotan</li>
<li>Naphthylpiperazine</li>
<li><a href="Nefazodone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nefazodone" title="Nefazodone">Nefazodone</a></li>
<li>Niaprazine</li>
<li>Oxypertine</li>
<li>Pardoprunox</li>
<li><a href="Para-Chlorophenylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Para-Chlorophenylpiperazine" title="Para-Chlorophenylpiperazine">pCPP</a></li>
<li>pFPP</li>
<li><a href="Posaconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Posaconazole" title="Posaconazole">Posaconazole</a></li>
<li>S-14,506</li>
<li>S-14,671</li>
<li>S-15,535</li>
<li>SB-258,585</li>
<li>SB-271,046</li>
<li>SB-357,134</li>
<li>SB-399,885</li>
<li>Sonepiprazole</li>
<li>TFMPP</li>
<li>Tolpiprazole</li>
<li><a href="Trazodone.htm" tppabs="https://ptable.com/wiki/compounds/A/Trazodone" title="Trazodone">Trazodone</a></li>
<li>Urapidil</li>
<li>Vesnarinone</li>
<li>Vilazodone</li>
<li>Vortioxetine</li>
<li>WAY-100,135</li>
<li>WAY-100,635</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Benzylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzylpiperazine" title="Benzylpiperazine">Benzylpiperazines</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>2C-B-BZP</li>
<li>3-Methylbenzylpiperazine</li>
<li>Befuraline</li>
<li>Bifeprunox</li>
<li><a href="Buclizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Buclizine" title="Buclizine">Buclizine</a></li>
<li><a href="Benzylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzylpiperazine" title="Benzylpiperazine">BZP</a></li>
<li>Chlorbenzoxamine</li>
<li>DBZP</li>
<li>Fipexide</li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>MBZP</li>
<li>MDBZP</li>
<li><a href="Meclozine.htm" tppabs="https://ptable.com/wiki/compounds/A/Meclozine" title="Meclozine" class="mw-redirect">Meclozine</a></li>
<li>Methoxypiperamide</li>
<li>Piberaline</li>
<li>Piribedil</li>
<li>Sunifiram</li>
<li>Trimetazidine</li>
<li>Vesnarinone</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Diphenylmethylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Diphenylmethylpiperazine" title="Diphenylmethylpiperazine">Diphenylalkylpiperazines</a><br><small>(benzhydrylalkylpiperazines)</small></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>AD-1211</li>
<li><a href="Almitrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Almitrine" title="Almitrine">Almitrine</a></li>
<li>Amperozide</li>
<li>BRL-15,572</li>
<li><a href="Buclizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Buclizine" title="Buclizine">Buclizine</a></li>
<li>BW373U86</li>
<li><a href="Cetirizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetirizine" title="Cetirizine">Cetirizine</a></li>
<li>Chlorbenzoxamine</li>
<li><a href="Chlorcyclizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorcyclizine" title="Chlorcyclizine">Chlorcyclizine</a></li>
<li><a href="Cinnarizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cinnarizine" title="Cinnarizine">Cinnarizine</a></li>
<li>Clocinizine</li>
<li><a href="Cyclizine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclizine" title="Cyclizine">Cyclizine</a></li>
<li>DBL-583</li>
<li>Diphenpipenol</li>
<li><a href="Diphenylmethylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Diphenylmethylpiperazine" title="Diphenylmethylpiperazine">Diphenylmethylpiperazine</a></li>
<li>Dotarizine</li>
<li>DPI-221</li>
<li>DPI-287</li>
<li>DPI-3290</li>
<li><span class="new">GBR-12,783</span></li>
<li>GBR-12,935</li>
<li><span class="new">GBR-13,069</span></li>
<li><span class="new">GBR-13,098</span></li>
<li><span class="new">GBR-13,119</span></li>
<li><a href="Hydroxyzine.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydroxyzine" title="Hydroxyzine">Hydroxyzine</a></li>
<li><a href="Lidoflazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lidoflazine" title="Lidoflazine">Lidoflazine</a></li>
<li>Manidipine</li>
<li><a href="Meclozine.htm" tppabs="https://ptable.com/wiki/compounds/A/Meclozine" title="Meclozine" class="mw-redirect">Meclozine</a></li>
<li>MT-45</li>
<li><a href="Oxatomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxatomide" title="Oxatomide">Oxatomide</a></li>
<li>SNC-80</li>
<li><a href="Vanoxerine.htm" tppabs="https://ptable.com/wiki/compounds/A/Vanoxerine" title="Vanoxerine">Vanoxerine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Pyrimidinylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pyrimidinylpiperazine" title="Pyrimidinylpiperazine">Pyrimidinylpiperazines</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Buspirone.htm" tppabs="https://ptable.com/wiki/compounds/A/Buspirone" title="Buspirone">Buspirone</a></li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li>Eptapirone</li>
<li>Gepirone</li>
<li>Ipsapirone</li>
<li>Piribedil</li>
<li>Prazitone</li>
<li><a href="Pyrimidinylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pyrimidinylpiperazine" title="Pyrimidinylpiperazine">Pyrimidinylpiperazine</a></li>
<li>Revospirone</li>
<li>Tandospirone</li>
<li>Tirilazad</li>
<li>Trimazosin</li>
<li>Umespirone</li>
<li>Zalospirone</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Pyridinylpiperazines</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Atevirdine</li>
<li>Azaperone</li>
<li><a href="Delavirdine.htm" tppabs="https://ptable.com/wiki/compounds/A/Delavirdine" title="Delavirdine">Delavirdine</a></li>
<li><a href="Mirtazapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mirtazapine" title="Mirtazapine">Mirtazapine</a></li>
<li>Pyridinylpiperazine</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Benzothiazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzothiazole" title="Benzothiazole">Benzo(iso)thiazolyl</a><a href="Piperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Piperazine" title="Piperazine">piperazines</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Lurasidone</li>
<li>Perospirone</li>
<li>Revospirone</li>
<li>Tiospirone</li>
<li><a href="Ziprasidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ziprasidone" title="Ziprasidone">Ziprasidone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Tricyclics<br><small>(piperazine attached via side chain)</small></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Amoxapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amoxapine" title="Amoxapine">Amoxapine</a></li>
<li>Clopenthixol</li>
<li>Clorotepine</li>
<li><a href="Clozapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Clozapine" title="Clozapine">Clozapine</a></li>
<li><span class="new">Cyanothepin</span></li>
<li><span class="new">Doclothepin</span></li>
<li><span class="new">Docloxythepin</span></li>
<li><a href="Flupentixol.htm" tppabs="https://ptable.com/wiki/compounds/A/Flupentixol" title="Flupentixol">Flupentixol</a></li>
<li><a href="Fluphenazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluphenazine" title="Fluphenazine">Fluphenazine</a></li>
<li><span class="new">Isofloxythepin</span></li>
<li><a href="Loxapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Loxapine" title="Loxapine">Loxapine</a></li>
<li><span class="new">Meperathiepin</span></li>
<li>Metitepine</li>
<li><span class="new">Octomethothepin</span></li>
<li><a href="Olanzapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Olanzapine" title="Olanzapine">Olanzapine</a></li>
<li>Opipramol</li>
<li><span class="new">Oxyclothepin</span></li>
<li><span class="new">Oxyprothepin</span></li>
<li><span class="new">Peradithiepin</span></li>
<li>Perathiepin</li>
<li>Perazine</li>
<li><a href="Perphenazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Perphenazine" title="Perphenazine">Perphenazine</a></li>
<li><a href="Pirenzepine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pirenzepine" title="Pirenzepine">Pirenzepine</a></li>
<li><a href="Prochlorperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Prochlorperazine" title="Prochlorperazine">Prochlorperazine</a></li>
<li><a href="Thiethylperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiethylperazine" title="Thiethylperazine">Thiethylperazine</a></li>
<li><a href="Thiothixene.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiothixene" title="Thiothixene" class="mw-redirect">Thiothixene</a></li>
<li><a href="Trifluoperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Trifluoperazine" title="Trifluoperazine">Trifluoperazine</a></li>
<li><span class="new">Trifluthepin</span></li>
<li><a href="Zuclopenthixol.htm" tppabs="https://ptable.com/wiki/compounds/A/Zuclopenthixol" title="Zuclopenthixol">Zuclopenthixol</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others/Uncategorized</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>6-Nitroquipazine</li>
<li>Azimilide</li>
<li>Cinepazet</li>
<li>Cinepazic acid</li>
<li>Cinepazide</li>
<li>Cyclohexylpiperazine</li>
<li>EGIS-7625</li>
<li>Hexocyclium</li>
<li><a href="Indinavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Indinavir" title="Indinavir">Indinavir</a></li>
<li>JNJ-7777120</li>
<li>Lodenafil</li>
<li>Mirodenafil</li>
<li>PB-28</li>
<li>Quipazine</li>
<li><a href="Ranolazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ranolazine" title="Ranolazine">Ranolazine</a></li>
<li>SA-4503</li>
<li><a href="Sildenafil.htm" tppabs="https://ptable.com/wiki/compounds/A/Sildenafil" title="Sildenafil">Sildenafil</a></li>
<li><a href="Tadalafil.htm" tppabs="https://ptable.com/wiki/compounds/A/Tadalafil" title="Tadalafil">Tadalafil</a></li>
<li><a href="Vardenafil.htm" tppabs="https://ptable.com/wiki/compounds/A/Vardenafil" title="Vardenafil">Vardenafil</a></li>
<li>VUF-6002</li>
<li>WY-46824</li>
<li>Zipeprol</li></ul>
</div></td></tr></tbody></table></div>













<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-12" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Dasatinib&oldid=972443856  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Dasatinib&oldid=972443856'" tppabs="https://en.wikipedia.org/wiki/?title=Dasatinib&oldid=972443856">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>